Capstone Investment Advisors
PCRX icon

Capstone Investment Advisors’s Pacira BioSciences PCRX Stock Holding History

Capstone Investment Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,171
Closed -$494K – 1936
2025
Q3 		$494K Buy
+19,171
New +$471K ﹤0.01% 1384
2024
Q3 		– Sell
-7,168
Closed -$205K – 2123
2024
Q2 		$205K Sell
7,168
-3,581
-33% -$102K ﹤0.01% 1762
2024
Q1 		$314K Buy
+10,749
New +$330K ﹤0.01% 1811
2023
Q4 		– Sell
-7,073
Closed -$217K – 2327
2023
Q3 		$217K Buy
+7,073
New +$255K ﹤0.01% 1774
2016
Q4 		– Sell
-6,000
Closed -$205K – 1068
2016
Q3 		$205K Buy
+6,000
New +$235K ﹤0.01% 682

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return